BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsai WS, Hsieh PS, Yeh CY, Chiang JM, Tang R, Chen JS, Changchien CR, Wang JY. Long-term survival benefits of adjuvant chemotherapy by decreasing incidence of tumor recurrence without delaying relapse in stage III colorectal cancer. Int J Colorectal Dis. 2011;26:1329-1338. [PMID: 21556841 DOI: 10.1007/s00384-011-1214-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu KC, Yo YT, Huang RL, Wang YC, Liao YP, Huang TS, Chao TK, Lin CK, Weng SJ, Ma KH, Chang CC, Yu MH, Lai HC. Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor. Oncotarget 2013;4:2366-82. [PMID: 24280306 DOI: 10.18632/oncotarget.1424] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
2 Jabbari E, Sarvestani SK, Daneshian L, Moeinzadeh S. Optimum 3D Matrix Stiffness for Maintenance of Cancer Stem Cells Is Dependent on Tissue Origin of Cancer Cells. PLoS One 2015;10:e0132377. [PMID: 26168187 DOI: 10.1371/journal.pone.0132377] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 9.8] [Reference Citation Analysis]
3 高波, 李兴华. 替吉奥单药在晚期结直肠癌辅助化疗中的疗效. 世界华人消化杂志 2014; 22(18): 2650-2656 [DOI: 10.11569/wcjd.v22.i18.2650] [Reference Citation Analysis]
4 Tsai WS, Hsieh PS, Yeh CY, Chiang JM, Tang R, Chen JS, Changchien CR, Wang JY. Impact of chemotherapy-related prognostic factors on long-term survival in patients with stage III colorectal cancer after curative resection. Int J Clin Oncol 2013;18:242-53. [PMID: 22262452 DOI: 10.1007/s10147-011-0370-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
5 Liu F, Tong T, Huang D, Yuan W, Li D, Lin J, Cai S, Xu Y, Chen W, Sun Y, Zhuang J. CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial. BMJ Open 2019;9:e017637. [PMID: 30700474 DOI: 10.1136/bmjopen-2017-017637] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]